Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ONVO 
Organovo Holdings Inc (ONVO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/07/2025: ONVO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -66.84% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/07/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.53M USD | Price to earnings Ratio - | 1Y Target Price 64.8 |
Price to earnings Ratio - | 1Y Target Price 64.8 | ||
Volume (30-day avg) 15548613 | Beta 1.13 | 52 Weeks Range 1.80 - 21.96 | Updated Date 04/7/2025 |
52 Weeks Range 1.80 - 21.96 | Updated Date 04/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -14450% |
Management Effectiveness
Return on Assets (TTM) -123.36% | Return on Equity (TTM) -378.4% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3686373 | Price to Sales(TTM) 28.92 |
Enterprise Value 3686373 | Price to Sales(TTM) 28.92 | ||
Enterprise Value to Revenue 30.22 | Enterprise Value to EBITDA -0.34 | Shares Outstanding 1800000 | Shares Floating 1286856 |
Shares Outstanding 1800000 | Shares Floating 1286856 | ||
Percent Insiders 1.52 | Percent Institutions 12.21 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Organovo Holdings Inc
Company Overview
History and Background
Organovo Holdings, Inc. was founded in 2007. It aimed to develop functional, three-dimensional human tissues for medical research and therapeutic applications. It focused on 3D bioprinting technologies. However, operations were wound down, and the company ceased operations in 2019.
Core Business Areas
- 3D Bioprinting Technology: Developed and commercialized a 3D bioprinting platform for creating functional human tissues.
- Therapeutic Tissue Development: Aimed to develop bioprinted tissues for liver and kidney diseases.
- Research Solutions: Provided bioprinted tissues and services to pharmaceutical and academic researchers.
Leadership and Structure
The company was led by a CEO and had a board of directors. Its organizational structure included research and development, sales, and marketing departments. The final CEO was Taylor J. Crouch.
Top Products and Market Share
Key Offerings
- ExVive Human Liver Tissue: A 3D bioprinted liver tissue model used for drug discovery and toxicology testing. Estimated market share: Unknown. Competitors: Insphero, CN Bio Innovations.
- ExVive Human Kidney Tissue: A 3D bioprinted kidney tissue model used for drug discovery and toxicology testing. Estimated market share: Unknown. Competitors: Insphero, CN Bio Innovations.
Market Dynamics
Industry Overview
The bioprinting industry is a rapidly growing field focused on creating functional tissues and organs for research and therapeutic applications.
Positioning
Organovo aimed to be a leader in 3D bioprinting, but closed its doors in 2019 due to financial struggles.
Total Addressable Market (TAM)
TAM estimates for the bioprinting market vary widely, ranging into billions of dollars. Organovou2019s position was initially strong, but their closure impacted their TAM relevance.
Upturn SWOT Analysis
Strengths
- Pioneering 3D bioprinting technology
- Proprietary NovoGel and NovoHold bioprinting platforms
- Established collaborations with pharmaceutical companies
Weaknesses
- High cash burn rate
- Limited revenue generation
- Dependence on research grants and partnerships
- Technological scalability challenges
Opportunities
- Expanding applications of bioprinted tissues in drug discovery and personalized medicine
- Partnerships with pharmaceutical companies for drug development
- Development of bioprinted organs for transplantation
- Growing interest in alternatives to animal testing
Threats
- Regulatory hurdles for bioprinted products
- Competition from other bioprinting companies
- Technological advancements by competitors
- Ethical concerns surrounding bioprinting
Competitors and Market Share
Key Competitors
- CN BIO Innovations
- Insphero
- Prellis Biologics
Competitive Landscape
Organovo initially had a competitive advantage with its early mover status. However, its financial struggles allowed competitors like CN Bio Innovations and Insphero to gain more market share. ONVO no longer competes since closing operations.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Organovo experienced initial growth in terms of technological development and partnerships but struggled with commercialization and revenue generation.
Future Projections: N/A - The company ceased operations in 2019. Future projections are no longer applicable.
Recent Initiatives: Prior to closing, initiatives included focusing on drug discovery partnerships and developing new bioprinted tissue models.
Summary
Organovo Holdings Inc. pioneered 3D bioprinting but faced significant challenges in commercialization and profitability. The company struggled with high operating expenses and insufficient revenue, leading to its closure in 2019. Despite its innovative technology, Organovo's financial performance was unsustainable. The lack of revenue generation proved fatal, highlighting the risks associated with early-stage biotechnology companies.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings (prior to delisting)
- Industry Reports
- Market Research Reports
- Company Press Releases (prior to closure)
- Publicly Available Financial Data
Disclaimers:
The information provided is based on historical data and information available prior to Organovo Holdings Inc.'s closure. Market share estimates are approximate and based on available industry data. This analysis is for informational purposes only and should not be considered investment advice. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Organovo Holdings Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2012-02-14 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.organovo.com |
Full time employees 14 | Website https://www.organovo.com | ||
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was incorporated in 2007 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.